Cambrex continues expanding, adding jobs at North Carolina site

Rapidly growing API maker Cambrex is turning its operations in High Point, North Carolina into a clinical supply center of excellence. (Cambrex)

Cambrex, which last week completed a $425 million deal to buy Halo Pharma and its two manufacturing sites, is expanding its facilities in North Carolina.

The East Rutherford, New Jersey-based API maker announced it will acquire a leased 35,000-square-foot facility it operates in High Point, as well as an adjacent 45,000-square-foot building. The API maker intends to establish a “center of excellence” for API clinical supply and process development.

The facilities will be fitted with kilo-scale and pilot-scale vessels, continuous reaction production, and chemistry, engineering and analytical development laboratories. The company declined to provide the cost of the investment but said the expansion will add to improvements made at the High Point operations which were picked up in its $25 million acquisition of PharmaCore in 2016. When the expansion is complete, the company expects to have 150 employees at the facility, triple the number when it got the site.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“Since we acquired the former PharmaCore business, now Cambrex High Point, in October 2016, we have invested over $5 million at the site and this is set to continue with both the strategic building acquisition and subsequent fit-out,” Cambrex CEO Steven Klosk said in a statement.

RELATED: Cambrex buying Pharmacore in $25M deal

The site produces complex APIs and intermediates in batch sizes from milligrams to 100 kg in support of clinical trials from phase 1 through to phase 3. The site is licensed with the DEA to manufacture Schedule II to Schedule V controlled substances.

Cambrex, which has been steadily expanding, last week closed its acquisition of dosage-form CDMO Halo Pharma. Cambrex picked up manufacturing sites in Whippany, New Jersey, and Montreal, comprising a total of 430,000 square feet of plant space. Its 450-person workforce joins Cambrex’s 1,200 employees across the U.S. and Europe.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.